Insight journal, Insight journal - Company

Pharmacyclics: Partnering activity 2009-2014

Posted on 20 October 2014

Tags: ,

Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline.

The number of partnering deals announced since 2009 stands at around 10 partnering deals covering licensing, collaboration, asset purchase, and development.

The following figure shows the level of Pharmacyclics partnering deal announcements since 2009.

The company clearly has not followed a consistent pattern in partnering and engages in collaborations only to bolster its existing pipeline.

Figure 1: Pharmacyclics partnering deals 2009-2014

Figure 1: Pharmacyclics partnering deals 2009-2014

Figure 1: Pharmacyclics partnering deals 2009-2014

Source: Current Agreements, 2014

Analysis of the partnering deals shows a strong inclination to deal making in cancer therapeutics.

The following table provides an overview of the partnering deals announced by Pharmacyclics based on specific cancer areas disclosed. The company partners for chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma and solid tumors amongst other types of cancer. Our report provides a more detailed insight into the precise therapeutic target of each deal.

 

See: Partnering Agreements with Pharmacyclics 2009-2014

Figure 2: Pharmacyclics partnering deals by therapy area 2009-2014

Figure 2: Pharmacyclics partnering deals by therapy area 2009-2014

Figure 2: Pharmacyclics partnering deals by therapy area 2009-2014

Source: Current Agreements, 2014

Further analysis of these deals shows that Pharmacyclics has a preference for licensing, supply and marketing deals.

The following table provides an overview of the partnering deals announced by Pharmacyclics based on deal type disclosed.

Figure 3: Pharmacyclics partnering deals by deal type 2009-2014

Figure 3: Pharmacyclics partnering deals by deal type 2009-2014

Figure 3: Pharmacyclics partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

Pharmacyclics has a number of products in its development pipeline at different stages of development. It is clear from the figure below that the company partners extensively in phase I and II stage of development; our records points to deals entered with Bristol-Myers Squibb, Janssen Research & Development, Servier and Celera to name a few companies.

The following table provides an overview of the partnering deals announced by Pharmacyclics based on stage of development at signature.

Figure 4: Pharmacyclics partnering by stage of development 2009-2014

Figure 4: Pharmacyclics partnering by stage of development 2009-2014

Figure 4: Pharmacyclics partnering by stage of development 2009-2014

Source: Current Agreements, 2014

Pharmacyclics has signed 10 partnering and licensing deals since 2009. The following provides two of the top deals by headline value signed by Pharmacyclics.

Figure 5: Top Pharmacyclics partnering deals by headline value 2009-2014

Figure 5: Top Pharmacyclics partnering deals by headline value 2009-2014

Figure 5: Top Pharmacyclics partnering deals by headline value 2009-2014

 

Source: Current Agreements, 2014

Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Pharmacyclics 2009-2014

Pharmacyclics partnering at Current Agreements

View all partnering deals for Pharmacyclics: 2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at CurrentAgreements (subscription required)

More

Partnering interests for Pharmacyclics

No M&A activity for Pharmacyclics

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Big Biotech

Available resources for deal coverage for Pharmacyclics

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Pharmacyclics company profile, recent partnering, M&A and financing news and articles

 

Related

View: Current Partnering Insight’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering Insight’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering Insight’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Partnering Activity – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Partnering Activity – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply